NCT02478320View on ClinicalTrials.gov

Phase II Study of Ilorasertib (ABT348) in Patients With CDKN2A Deficient Solid Tumors

PHASE2TerminatedINTERVENTIONAL

Enrollment

12

Participants

Timeline

Start Date

August 5, 2016

Primary Completion Date

May 12, 2022

Study Completion Date

May 12, 2022

Conditions

Advanced Cancers

Interventions

DRUG

Ilorasertib

200 mg administered by mouth twice daily on Days 1, 8, and 15 of each 28-day cycle.

Trial Locations (1)

77030

University of Texas MD Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

AbbVie

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER